Comparative Pharmacology
Head-to-head clinical analysis: ENTERO VU 24 versus EOVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENTERO VU 24 versus EOVIST.
ENTERO VU 24% vs EOVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Entero-Vu 24% is a radiopaque contrast agent containing barium sulfate. It acts by coating the gastrointestinal mucosa, providing positive contrast on radiographs due to barium's high atomic number, which attenuates X-rays.
Gadoxetic acid is a hepatocyte-specific MRI contrast agent. It is taken up by hepatocytes via organic anion transporting polypeptides (OATP1B1 and OATP1B3) and excreted into bile via multidrug resistance-associated protein 2 (MRP2). The paramagnetic gadolinium ion shortens T1 relaxation time, enhancing signal intensity in liver tissue on T1-weighted images.
Adults: 50 mL of 24% solution orally as a single dose, repeated once after 30 minutes if needed.
0.1 mL/kg body weight (0.025 mmol Gd/kg) intravenously as a bolus injection, followed by a saline flush of at least 5 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 1.5 hours (range 1.2–1.8 h) in patients with normal renal function; half-life is prolonged in renal impairment, correlating with glomerular filtration rate.
Renal: 100% of absorbed iodine is excreted unchanged in urine within 24-48 hours; no biliary or fecal elimination of significance.
Primarily renal elimination: 95% of the administered dose is excreted unchanged in urine within 72 hours; less than 1% eliminated via biliary/fecal route.
Category C
Category C
Diagnostic Imaging Contrast Agent
Diagnostic Imaging Contrast Agent